The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
But results come from a curated dataset, with no in-trial comparator.
Global data are in the same ballpark as Chinese results presented earlier this year.
A common mutation comes into play for PRMT5 inhibition.
Tolerability could decide first-line therapy in EGFRm disease.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
